about
Does antiviral therapy reduce complications of cirrhosis?Occult hepatitis B virus infectionAutoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation.Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?Hepatitis B viral load affects prognosis of hepatocellular carcinoma.Association of polymorphism in microRNA 604 with susceptibility to persistent hepatitis B virus infection and development of hepatocellular carcinomaHepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in korean patients with chronic hepatitis B.Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B PatientsEffective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal veinRetrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomesTenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in KoreaPrior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance.Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments.Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.Current status and strategies for hepatitis B control in Korea.Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer.Association of polymorphism in MicroRNA 219-1 with clearance of hepatitis B virus infection.Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization.Nucleos(t)ide Analogue Treatment for Adult Patients with HBeAg-positive Chronic Infection with Genotype C Hepatitis B Virus: A Nationwide Real-life Study.The association between microRNA-323b polymorphism and hepatitis B virus persistent infection - some problems should be addressed.Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area.Cetylpyridinium chloride as a novel inhibitor of hepatitis B viral capsid assembly.Entecavir and Tenofovir Reduce Hepatitis B Virus-related Hepatocellular Carcinoma Recurrence More Effectively than Other Antivirals.Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.Genetic association of complement component 2 variants with chronic hepatitis B in a Korean population.A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
P50
Q26851410-4BCF6921-AC60-4CB6-B0C7-3FC70AE9DCA1Q27004224-CE06D2A5-E4F3-4DBC-8DC6-4AA7F03C2EB8Q30244056-AC5EE9D7-379F-4C80-A7D6-2006279E2085Q34045477-E2A494B2-65D5-43F0-9DE6-ADB7F7B6A28DQ34083775-1FB6FB14-2978-4FE0-AF02-262D5CC94643Q34168459-7EACBBDE-0D1E-4049-BD56-28F3FEDA4670Q34528580-EEF35617-3B67-46B3-9B97-39985B11A5CFQ35144067-9AC24E90-EAB7-40AB-BC53-33BB5AED68B9Q35677233-1E5FC464-B025-4B5C-9494-6A09FC037975Q35715947-6F731FBC-52EC-4DFA-A521-B1FD15F52C59Q35824081-E5499E57-08E0-4C30-9993-4E26A66AE4FFQ36067839-828196DA-5DD5-4F2F-9484-66B2304087A7Q36460249-9661AD3D-0E1E-4DC9-A875-958A7BD661A2Q37643680-1EFFC0DB-BA42-4451-9233-8320EA568286Q38724288-E2CFBECD-8063-403A-9DDF-C797C56ED0CEQ40261148-11CCD479-8860-4D98-8BB3-993BD1144F56Q40859411-64AD54B4-8DE6-49A9-A81D-14CD33142C12Q41122301-DBF81837-C247-4EBA-8971-385E2005CB1DQ41175515-57BDF39C-43FF-4A54-ACFD-594FED98CC8BQ41454651-E0C05576-B6C6-4872-8840-515939FA89A1Q41466695-F2BBB57C-FABF-4E73-B5D6-9534AFA23CFDQ41471174-B0BE1090-9257-436B-9909-E7330129B84BQ41528269-A98EEE2D-2604-4857-B0E0-5F54F1907607Q41538789-863312C7-807A-4EFE-81FD-EA23CB1D5C77Q41931192-4846EB56-CF2E-4A57-8514-B7EE4A0A5AEAQ42019561-213D39C5-A2FD-4BDF-8A4F-6FF201BFFC55Q44466854-453D6FD0-E20F-4311-A0E3-AF0B71ED4E9BQ44646709-82DF4C8F-D65B-4477-AD98-03AB7666B582Q45323951-F2CB8A9C-D138-4E83-8260-38CE184093FEQ45326396-C7F2576D-0749-4DF1-B0D0-5B631E7ED5B8Q45341894-50F33F9C-9D2C-4FBE-8316-3456F27A4C05Q45361180-E4E18E5C-11AD-415A-9355-E5BEA9AD1F55Q47550955-408E7ED7-EF87-47AC-A9E1-BA5F57347CDDQ47556469-355A8EBF-FFA3-4FFC-8253-9055115FA52FQ47570592-79356AA4-DB25-422A-98FA-6C0D25F9DA81Q47589759-1FF7892B-E903-4CE9-B1F9-CABDC4456998Q47761128-AD46D6DC-69A0-4C2A-B441-CB3DCC2D51D6Q47795711-1EA961C8-6A7C-468D-8E53-09F1BC153030Q48182745-1BAD7406-87FF-433E-84A5-928FC64E87EBQ48208576-318D469F-BC3E-4FA9-981E-5B32D50DE7F1
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Yoon Jun Kim
@en
Yoon Jun Kim
@nl
type
label
Yoon Jun Kim
@en
Yoon Jun Kim
@nl
prefLabel
Yoon Jun Kim
@en
Yoon Jun Kim
@nl
P31
P496
0000-0001-9141-7773